Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

New research sheds light on how ketamine affects the brain by targeting a specific NMDA receptor subtype, GluN1-2B-2D.

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Weekly treatment with low doses of the GLP-1 receptor agonist semaglutide (Ozempic) reduced alcohol consumption and craving ...

Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Patients with glaucoma who are using prostaglandin F (FP) receptor agonists to control their disease may experience ...